Luxembourg, Luxembourg Hunza Ventures appeared to be the VC, which was created in 1998. The leading representative office of defined VC is situated in the Luxembourg. The fund was located in Europe if to be more exact in Luxembourg.
This Hunza Ventures works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2009. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2015. The fund is constantly included in less than 2 deals per year.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Hunza Ventures, startups are often financed by S.R.I.W., Life Sciences Research Partners V.Z.W., Grifols. The meaningful sponsors for the fund in investment in the same round are Grifols, Vinnof, Life Sciences Research Partners V.Z.W.. In the next rounds fund is usually obtained by Grifols, EASME - EU Executive Agency for SMEs.
Among the various public portfolio startups of the fund, we may underline Celyad Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Belgium. Among the most successful fund investment fields, there are Medical Device, Therapeutics.
Related Funds
| Fund Name | Location |
| Congress Avenue Ventures | - |
| Diamond BioFund | New Taipei, Taiwan |
| Fortress Investment Group | New York, New York, United States |
| Founders Capital Partners | California, Santa Barbara, United States |
| Quantum Angels | - |
| Silverleaf Venture Partners | Connecticut, Stamford, United States |
| Siri Software GmbH | - |
| XDL Capital Group | Canada, Ontario, Toronto |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ITeos Therapeutics | $10M | 03 May 2012 | Cambridge, Massachusetts, United States | ||
Celyad | $8M | 19 Jan 2009 | Walloon Brabant |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ITeos Therapeutics | $10M | 03 May 2012 | Cambridge, Massachusetts, United States | ||
Celyad | $8M | 19 Jan 2009 | Walloon Brabant |
